Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2858521 | 0.99 | L3MBTL1 (0.54) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL2863422 | 0.93 | L3MBTL1 (0.58) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL29297383 | 0.89 | ALDH1A1 (0.58) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL5520151 | 0.88 | FKBP1A (0.48) | L3MBTL1POLBSIGMAR1 | |
| SCHEMBL28879461 | 0.88 | FKBP1A (0.48) | L3MBTL1POLBSIGMAR1 | |
| SCHEMBL11147455 | 0.88 | MEN1 (0.55) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL9581725 | 0.87 | L3MBTL1 (0.55) | L3MBTL1ATMALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL3309475 | 0.87 | MEN1 (0.54) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL3306018 | 0.87 | MEN1 (0.54) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL22620870 | 0.87 | S1PR5 (0.47) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2025101881-A1 | HETEROATOM CONTAINING PEPTIDOMIMETICS TARGETING VIRAL PROTEASES | EMORY UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-3490993-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2023-12-06 | — | — | EP | disclosed |
| CN-116615428-A | Tricyclic pyridones and pyrimidinones | 医睿世康药业研发公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4217071-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-5500426-A | ADMINISTERED TO IMPROVE GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-03-19 | — | — | US | disclosed |
| US-5492912-A | IMPROVES GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-02-20 | — | — | US | disclosed |
| EP-0638568-A1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-02-15 | — | — | EP | disclosed |
| US-5382584-A | Antiischemic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0582164-A1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | Bristol-Myers Squibb Company (US) | 1994-02-09 | — | — | EP | disclosed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4200628-A | ANTIBIOTICS, BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1980-04-29 | — | — | US | disclosed |
| EP-0001643-A2 | Aminoglycoside derivatives, process for their manufacture, pharmaceutical compositions and carboxylic acids | SHIONOGI & CO., LTD. (JP) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | L3MBTL1 1230/4885ATM 3565/4885ALDH1A1 1493/4885 |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | DHFR, TYMS, TYMP | L3MBTL1 4297/4885ATM 3646/4885ALDH1A1 564/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | L3MBTL1 3383/4885ATM 1003/4885ALDH1A1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.